Welcome to our dedicated page for Outlook Therapeutics SEC filings (Ticker: OTLK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial updates, FDA correspondence, and frequent capital raises can make Outlook Therapeutics’ SEC disclosures feel like a maze. Whether you are scanning a 300-page 10-K for cash-runway details or piecing together Form 4 insider trading data before the next ONS-5010 milestone, the technical language alone can drain hours.
Stock Titan solves that problem with AI-powered summaries that translate each document into clear insights. Our platform flags the sections that matter—R&D spending trends in the Outlook Therapeutics quarterly earnings report 10-Q filing, executive pay in the latest proxy, and every Outlook Therapeutics Form 4 insider transactions real-time. Need to compare clinical trial disclosures across periods? One click delivers side-by-side analysis. You’ll also find:
- Instant alerts for Outlook Therapeutics 8-K material events explained
- AI context on dilution risk from shelf registrations
- Concise tables that connect ONS-5010 trial phases to projected cash needs
- Direct links to each exhibit, so you can verify numbers in seconds
Investors use these tools to track FDA review timelines, monitor Outlook Therapeutics executive stock transactions Form 4, and decide if funding levels support ongoing trials. From an Outlook Therapeutics annual report 10-K simplified to the latest Outlook Therapeutics insider trading Form 4 transactions, every document arrives within minutes of hitting EDGAR, already parsed and searchable. If you have ever typed “understanding Outlook Therapeutics SEC documents with AI” or looked for an “Outlook Therapeutics earnings report filing analysis,” you’re in the right place—complex biotech filings, made clear.
Great Point Partners, LLC together with Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl report beneficial ownership of 2,220,000 shares of Outlook Therapeutics, Inc. common stock, representing 4.99% of the outstanding shares based on 42,192,728 shares reported by the issuer. The holdings consist of warrants to purchase 2,220,000 shares, which are treated as beneficially owned but are subject to an exercise restriction (a Beneficial Ownership Cap) that prevents exercise if it would increase ownership above 9.99%.
The reporting persons disclose shared voting and dispositive power over the 2,220,000 shares and state the position is not held to influence control of the issuer. The filing is a joint Schedule 13G/A and includes a Joint Filing Agreement executed August 14, 2025.
Outlook Therapeutics, Inc. (OTLK) reports commercial availability of LYTENAVA (bevacizumab gamma) in Europe in fiscal 2025 and recognizes revenue when product is delivered to pharmaceutical wholesalers, with returns, rebates and administrative fees contractually applied. The company has 260,000,000 shares authorized and reported 43,479,051 shares issued and outstanding at June 30, 2025 versus 23,905,635 at September 30, 2024.
The filing details multiple financing transactions in 2025 including a public offering that generated net proceeds of $11,625,229, ATM capacity with $88,301,796 remaining as of June 30, 2025, and several warrant inducement transactions that produced net proceeds and resulted in mark-to-market and inducement charges (including $27,711,889 and $4,196,868 recorded for the nine months ended June 30, 2025). The company notes a March 2025 Note with conversion mechanics, high default interest (22% per annum) and potential dilution triggers. A securities class action is pending and a motion to dismiss is under review.
Outlook Therapeutics, Inc. Schedule 13G/A reports that Tang Capital entities and Kevin Tang collectively beneficially own 1,500,000 shares of the company's common stock, representing 3.4% of the outstanding class on a diluted basis. Those shares are currently issuable upon exercise of warrants held by Tang Capital Partners, LP, and the filing states the percentages are based on 43,692,728 shares (42,192,728 outstanding plus 1,500,000 issuable warrants). TCP's warrants are exercisable for one share each but include a beneficial ownership cap preventing exercise that would increase ownership above 9.99% unless TCP provides notice to increase to a maximum of 19.99% with a 61-day delay. Voting and dispositive power over the shares is shared among Tang Capital Management, Tang Capital Partners, LP and Kevin Tang.
FAQ
What is the current stock price of Outlook Therapeutics (OTLK)?
What is the market cap of Outlook Therapeutics (OTLK)?
